Get the Stockscreener App
4.34
7.69%
0.31
After Hours:
4.60
0.26
+5.99%
Pluri Inc stock is traded at $4.34, with a volume of 28,781.
It is up +7.69% in the last 24 hours and down -1.36% over the past month.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.
See More
Previous Close:
$4.03
Open:
$3.95
24h Volume:
28,781
Relative Volume:
2.70
Market Cap:
$27.25M
Revenue:
$598.00K
Net Income/Loss:
$-21.81M
P/E Ratio:
-1.0534
EPS:
-4.12
Net Cash Flow:
$-16.66M
1W Performance:
+11.42%
1M Performance:
-1.36%
6M Performance:
-8.63%
1Y Performance:
-17.33%
1-Day Range:
$3.95
$4.6734
1-Week Range:
$3.36
$4.6734
52-Week Range:
$3.33
$6.60
Pluri Inc Stock (PLUR) Company Profile
Name
Pluri Inc
Sector
Industry
Phone
972-74-710-7171
Address
MATAM ADVANCED TECHNOLOGY PARK, HAIFA
Compare PLUR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLUR
Pluri Inc
|
4.34 | 27.25M | 598.00K | -21.81M | -16.66M | -4.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Pluri Inc Stock (PLUR) Latest News
DarioHealth Announces CFO Transition - Benzinga
Pluri Inc. subsidiary loses $4.2 million NIAID contract By Investing.com - Investing.com Canada
Pluri Inc. subsidiary loses $4.2 million NIAID contract - Investing.com Australia
Pluri IncPluri Biotech Receives Termination Notice From Niaid Of ContractSEC Filing - marketscreener.com
Analyzing X4 Pharmaceuticals (NASDAQ:XFOR) & Pluri (NASDAQ:PLUR) - Defense World
Pluri Inc. (NASDAQ:PLUR) Short Interest Update - Defense World
Pluri’s immune cell expansion technologies gain patents - Yahoo Finance
Pluri Announces Expansion of Intellectual Property Portfolio wit - GuruFocus
Pluri secures patents for cancer cell therapy expansion tech By Investing.com - Investing.com South Africa
Pluri Inc. Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel - MarketScreener
Pluri secures patents for cancer cell therapy expansion tech - Investing.com India
Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel - TradingView
Pluri CEO Yaky Yanay on pioneering cell-tech solutions for global needs - Proactive financial news
Pluristem stock touches 52-week low at $4 amid market challenges By Investing.com - Investing.com South Africa
Pluristem stock touches 52-week low at $4 amid market challenges - Investing.com
BRAINSTORM CELL THERAPEUTICS INC. SEC 10-K Report - TradingView
Pluri Inc. (NASDAQ:PLUR) Sees Large Decrease in Short Interest - Defense World
Pluri Inc. sets date for 2025 annual shareholder meeting By Investing.com - Investing.com Canada
Pluri Inc. sets date for 2025 annual shareholder meeting - Investing.com India
Revolutionary Cell Therapy Preservation: Teknova's New PluriFreeze System Transforms Development Process - StockTitan
Stem Cell Stocks on the Rise: Companies Driving the $48 Billion Market Boom - openPR
Plurilock Security (CVE:PLUR) Shares Down 5% – Here’s What Happened - Defense World
Using cell science to fight nuclear weapons: How is Pluri revolutionizing health and food tech? - The Jerusalem Post
Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Forecast: Ke... - WhaTech
Pluri Inc. partners with Hemafund for radiation emergency response By Investing.com - Investing.com Canada
Pluri Inc. and Hemafund partner for radiation emergency pre By Investing.com - Investing.com Canada
Pluri signs deal to help Ukraine's radiation emergency preparedness - The Pharma Letter
Pluri, Hemafund Sign Exclusive Collaboration Deal on Potential Radiation Treatment; Shares Rise - Marketscreener.com
Pluri Inc. and Hemafund partner for radiation emergency pre - Investing.com India
Pluri Inc. partners with Hemafund for radiation emergency response - Investing.com
Pluri announces exclusive collaboration agreement with Hemafund - TipRanks
Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness - The Manila Times
Head-To-Head Survey: Pluri (NASDAQ:PLUR) & Kyverna Therapeutics (NASDAQ:KYTX) - Defense World
EAF and Buhler announce collaboration - TipRanks
Can This New Technology Finally Make Lab-Grown Meat Affordable? Ever After Foods Says Yes - StockTitan
Pluri Announces Strategic Merger to Enhance Market Position - TipRanks
Pluri Proposes Extension of Convertible Bond Maturity to Key Investor - TipRanks
Pluri: Fiscal Q2 Earnings Snapshot - CT Insider
Pluri Inc Stock (PLUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):